NEW YORK (GenomeWeb News) – Transgenomic said this week that Paul Kinnon has been named president, CEO, and a director of the company, replacing Craig Tuttle.
Kinnon joins Transgenomic from New Zealand-based ZyGem, where he served as president and CEO. Kinnon joined ZyGem in 2007 from Invitrogen, now part of Life Technologies, where he held the positions of vice president of global strategic alliances and vice president and general manager of the applied markets business unit. Prior to that, Kinnon held business, sales, and marketing roles at Guava Technologies (now part of Millipore), Cellomics (now part of Thermo Fisher Scientific), and other life science companies.
Tuttle served as president and CEO of Transgenomic since July 2006. He was previously the president and COO of Duke Scientific, a specialty particle technology company, and before that he was the president and CEO of Applied Biotech, a point-of-care rapid diagnostics manufacturer in the Apogent Technologies group.
BioMarker Strategies has appointed Jerry Parrott as its new president, CEO, and director, effective immediately. Parrott, formerly VP of corporate communications and public policy at Human Genome Sciences, will report to Jack Davis, head of BioMarker Strategies' board of directors.
Parrott also served as chairman and president of the Maryland Health Care Product Development Corporation and held various senior level positions with Bristol-Myers Squibb, American Hospital Supply Corporation, and Walgreen Company.
Proteomics-based diagnostics developer Prevencio has appointed H. Perry Fell to be chairman of the board and Rhonda Rhyne to be president, CEO, and board director.
Fell formerly was chairman and CEO of NanoString Technologies and he co-founded Seattle Genetics. Rhyne has been president of CardioDynamics, and she founded the consulting company Rhyne Life Sciences.
Pressure BioSciences said this week that Chief Financial Officer Conrad Mir has resigned from his post, effective immediately. He has been named CEO of Competitive Technologies (CTI), a biotech firm that distributes a pain therapy medical device, CTI said separately this week.
Pressure Bio has named Richard Thomley to serve as the firm's acting CFO. Thomley has been an independent financial consultant to the company since March.
Matrix-Bio, a metabolomics-based cancer diagnostics firm, has tapped Deborah Neff to serve on its board of directors. Neff has served as worldwide president of BD Biosciences and as CEO of Predicant Biosciences and Pathwork Diagnostics.
Diagnocure said this week that Chantal Mikloi has resigned her position as CFO effective Oct. 11.
The company said that Frederic Boivin, a senior director, will oversee financial matters, and Danielle Allard, a senior director of corporate affairs, will be responsible for filings to regulatory agencies.
Andrew Morris has joined SQI Diagnostics' board of directors.
Morris has been president and CEO of the Toronto-based molecular test developer since June. He replaces SQI Founder Peter Lea, who has resigned from the board. SQI said that Lea will continue to serve the company as an advisor.
C2N Diagnostics announced three new hires this week: Timothy Veenestra as senior vice president of diagnostic services and innovation; Philip Verghese as principal scientist; and Phillip Herrbrich as laboratory manager.
Veenestra was previously director of the laboratory of proteomics and analytical technologies at the National Cancer Institute. Verghese was a post-doctoral researcher in the laboratory of C2N scientific founder, Washington University researcher David Holtzman. Herrbrich brings experience from working within GLP and CLIA-regulated laboratory environments, including at Mid-America Transplant Services, Barnes-Jewish Hospital, and the Washington University School of Medicine.
Andy Ferrin has left Golden Helix to become a sales executive at Oracle Health Sciences. Ferrin had served as executive vice president of sales, business development, and services at Golden Helix, a Bozeman, Mont.-based bioinformatics company, for the past six years.
Patrick Schnable has been named Iowa Corn Promotion Board Endowed Chair in Genetics, a new faculty position within Iowa State University's agronomy department. In connection with the appointment, the board has invested $2 million to support the position and its research.
Schnable is an agronomy professor and is director of ISU's Center for Plant Genomics.
Gentris has hired John Doyle to serve as vice president of information technology to oversee the development of Gentris' IT infrastructure and to lead the implementation of BioFortis' Labmatrix and Qiagram software in its biorepository.
Prior to joining the company, Doyle worked at IBM as a programmer and a software engineer.
Eric Banks is now the team leader of the Broad Institute's Genome Sequencing and Analysis program. He is taking over for Mark DePristo, who is now VP of informatics at SynapDx.
Before joining the Broad in 2009, Banks earned an ME from the Massachusetts Institute of Technology and a PhD in computational biology from Princeton.
The National Institutes of Health has given 78 grants under its High Risk-High Reward Research Awards. Among those that will receive grants are Jay Shendure from the University of Washington and Sunney Xie from Harvard University, who will each receive the NIH Pioneer award to develop innovative approaches that impact biomedical or behavioral research.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.